Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Purple Biotech ( (PPBT) ) just unveiled an update.
On March 13, 2026, Israel-based Purple Biotech reported fourth-quarter and full-year 2025 results that underscored a strategic pivot toward its CAPTN-3 tri-specific antibody platform, advancing lead candidate IM1240 and naming IM1305 as a second development candidate. The company highlighted positive preclinical data, toxicology results showing an expanded therapeutic window for IM1240, and achievement of commercially viable manufacturing yields, while disclosing that legacy assets CM24 and NT219 have been impaired and will only progress with external funding or partners.
For the fourth quarter of 2025, Purple Biotech’s research and development and general and administrative expenses rose sharply, and a $20.5 million non-cash impairment on CM24 and NT219 drove a net loss of $23.6 million. For the full year 2025, net loss widened to $26.4 million despite lower clinical trial spending, but with cash and equivalents of $9.5 million at year-end and an expected runway into 2027, the company signaled it is financially positioned to push CAPTN-3 toward a planned Phase 1 trial of IM1240, reinforcing its focus on high-potential T cell engager and masked antibody modalities in oncology.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.
The score is held down primarily by the lack of revenue, ongoing losses, and negative free cash flow, indicating continued reliance on external funding. Technical indicators also point to a bearish trend with weak momentum. The main positive is the low-debt balance sheet, which reduces near-term leverage risk but does not offset weak operating fundamentals.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage immunotherapy company listed on Nasdaq and TASE that is developing a next-generation platform of masked tri-specific antibodies to treat cancer. Its lead CAPTN-3 platform is designed to target tumor antigens while engaging both T cells and NK cells, aiming to maximize anti-tumor potency and reduce toxicity for solid tumor indications.
Average Trading Volume: 14,007
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.93M
For detailed information about PPBT stock, go to TipRanks’ Stock Analysis page.